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The tumorpromoterPMA has been shownto induce accessorycell-independent
T cell proliferation in conjunction with mAbs specific for CD3, CD28, and CD2
(1-6). Inthese systems, PMA induces IL-2-R expression whilethe presence ofthese
mAbs is synergistic for the maximal expression of IL-2-R and IL-2 production.
Recently, we have identified the early activation antigen, EA 1, bythe generation
ofmAb specific for PMA-activated T cells (7). EA 1 expression is seen as early as
30 min after the addition ofPMA. EA 1 expression induced by PMA and mitogens
precedes that ofIL-2-R. Our further studies (8) show that protein kinase C activa-
tion is the primary pathway for the induction ofEA 1 expression and that calcium-
dependent pathways appear to have a secondary role. The EA 1 antigen is a series
ofdisulfide-linked dimers (32kD/32kD, 32kD/28kD,and28kD/28kD), with subunits
ofan identical 24-kDcore protein thatis phosphorylated anddifferentially glycosylated.
Recently, EA 1 hasbeen shown tobe expressed very early by fetal thymocytes during
ontogeny (Jung, L. K. L., B. F. Haynes, S. Pahwa, and S. M. Fu, manuscript sub-
mitted for publication).
In the initial study (7), mAb EA 1 was shown not to inhibit or to stimulate T
or B cell proliferation. Because of its early expression during T cell ontogeny and
activation and its molecular structure, the possibility that EA 1 plays an important
role ineither cellular interaction orinteractionwith ayet-to-be-definedgrowth factor
was suggested. Toexplorethis further, mAbswere generated against affinity-purified
EA 1. In this study, anew mAb against EA 1 was shown in collaboration with PMA
to induce T cells to express IL-2-R, to secrete IL-2, and to proliferate. This process
appeared to be independent ofmonocytes. Although this mAb by itselfdid not in-
duce an increase in [Ca"]i by PMA-treated T cells, crosslinking ofEA 1 molecules
caused a marked increase in [Ca2+];.
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Materials and Methods
Affinity Purification of EA 1 fromJurkat Cells.
￿
Anti-EA 1 mAb P8 (IgG2a) was prepared
as previously described (7). This mAb was purified from appropriate ascitic fluids by DEAE
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ion-exchange chromatography. The purified mAb P8 was coupled to Sepharose-4B beads
at a ratio of 3 mg antibody per ml of packed beads.
Jurkat cells were incubated with 10 ng/ml ofPMA (Sigma Chemical Co., St. Louis, MO)
for 12 h and washed with PBS containing 1 mM PMSF. Cell lysates were prepared by deter-
gent lysis at a concentration of 5 x 107 cells/ml with a lysis buffer containing 20 mM Tris-
HCI, pH 7.5, 0.15 M NaCl, 7.5 mM 3-[(3-cholamidopropyl)dimethylamine]-1-propanesulfo-
nate dehydrate (CHAPS),' 50 mM iodoacetamide, 1 mM PMSF, 1 U/ml aprotinin, 10 Wg/ml
leupeptin, 50 1Lg/ml trypsin inhibitor, 2 mM EDTA for 30 min at 4°C. The lysate was cen-
trifuged at 5,000 g for 30 min, then at 16,000 g for 2 h to remove nuclei and debris . A deter-
gent lysate from 10'° Jurkat cells was precleared with 10 ml of plain Sepharose-4B and
Sepharose-4B conjugated with normal mouse IgG. The precleared lysate was incubated with
5 ml of mAb P8-Sepharose-4B for 2 h at 4°C. The beads were packed into a column and
washed with the lysis buffer and a high-salt buffer containing 20 mM Tris-HCI, pH 7 .5, 0.6 M
NaCl, 5 mM CHAPS, 1 mM PMSF. The bound material was eluted with 50 mM diethyla-
mine, pH 11. The eluate was neutralized with 1 M NaH2PO4, dialyzed against PBS, and
concentrated. Q,uantitation of material recovered and assessment of purity were made by
SDS-PAGE and subsequent silver staining of the gel.
Production ofmAb Against EA 1.
￿
BALB/c mice were immunized with affinity-purified EA
1 molecules. For the primary immunization, 1 hg of EA 1 material was emulsified with an
equal volume of CFA. Further immunization was carried out with 1 l~g of immunogen in
IFA. Five injections were administered subcutaneously at 2-4-wk intervals. 2 mo after the
last immunization, mice were given an intraperitoneal boost of 2 Fig of EA 1 material. Spleens
were taken 3 d later. Hybridomas were generated using myeloma cell line SP2/0 as a fusion
partner as previously described (9). Hybridoma supernatants were screened by flow cytom-
etry against PMA-activated Jurkat cells, and by ability to augment PMA-induced prolifera-
tion . The selected hybridomas were cloned twice on soft agar.
Antibody isotype was determined by ELISA with isotype-specific rabbit anti-mouse Ig
antisera (Meloy Laboratories, Inc., Springfield, VA) and alkaline phosphatase-linked goat
anti-mouse Ig. The new mAb against EA 1, G38, was IgG2b. This mAb was purified from
ascitic fluids by DEAE ion-exchange chromatography.
Other mAbs.
￿
Two mAbs against CD3, designated T3-11 (IgGI) and 235 (IgM), were pre-
pared as previously described (1). ATl (anti-IL-2-R, IgGI) was prepared and biotinylated
as previously described (1). Purified anti-Leu-23 mAb (IgGI) was generously provided by
Dr. Lanier (Becton Dickinson & Co., Mountain View, CA) (10). As control mAbs, HDP-1
(anti-DNP, IgGI), SSl (anti-sheep erythrocyte, IgG2a), and NS8.1 (anti-sheep erythrocyte,
IgG2b) were used. These mAbs were generous gifts from Dr. I. Davie (Washington Univer-
sity, St. Louis, MO).
Cell Preparation.
￿
PBMC were isolated from buffy coats or peripheral blood from normal
donors using Ficoll-Hypaque density gradient centrifugation. T cells were obtained by SBRC
rosetting (11) and were usually 95% pure. These T cell preparations (E' cells) contained
1-2% monocytes by nonspecific esterase staining. To isolate monocyte-depleted T cells, T
cells were further separated by nylon wool column, plastic adherence, and carbonyl-iron treat-
ment (12-14) . These T cell preparations contained <0.1% monocytes.
Cells were cultured in complete medium consisting of RPMI-1640 (Gibco Laboratories,
Grand Island, NY) supplemented with 10% FCS (HyClone Laboratories, Logan, UT), 2 mM
L-glutamine, 50 U/ml penicillin, and 50 Etg/ml streptomycin (Gibco Laboratories).
Immunoprecipitation.
￿
Peripheral blood T cells (E' cells) activated with 10 ng/ml of PMA
for 18 h were labeled with "'I (New England Nuclear, Boston, MA) by the lactoperoxidase
technique (15). The labeled cells were washed with PBS containing 1 MM PMSF, 10 mM
iodoacetamide, and 0.02% NaN3. The cell lysates were prepared by detergent lysis at a con-
centration of 5 x 101 cells/ml for 15 min at 4'C in a lysis buffer containing 20 mM Tris-
HCl, pH 7 .5, 0.15 M NaCl, 7.5 mM CHAPS, 50 mM iodoacetamide, 1 mM PMSF, 1 U/ml
aprotinin, 10 P,g/ml leupeptin, 50 l~g/ml trypsin inhibitor, and 2 mM EDTA. After centrifu-
' Abbreviation used in this paper: CHAPS, 3-[(3-cholamidopropyl) dimethylaminel-l-propansulfonate
dihydrate.NAKAMURA ET AL.
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gation, the lysates were precleared three times with 50 ptl of Sepharose-4B conjugated with
goat anti-mouse Ig antibodies (3 mg/ml). The precleared lysates were added to 30 11 of
Sepharose-4B conjugatedwith goat anti-mouse Ig antibodies that had been incubated with
mAbs. The mixture was incubated for 60 min at 4°C with constant mixing, and then washed
six times with a buffer containing 10 mM Tris-HCI, pH 7.8, and 0.6 M NaCl. Three addi-
tional washings with a buffer containing 10 mM Tris-HC1, pH 8.8, 0.6 M NaCl, 0.1% SDS,
and 0.05% NP-40 were carried out. The absorbed proteins were released by boiling for 5
min in a sample buffer containing 0.125 M Tris-HCI, pH 6.8, 2% SDS, and 10% glycerol
(with or without 5% 2-ME). SDS-PAGE was carried out on 11% polyacrylamide gels by using
the discontinuous buffer system described by Laemmli (16). Gels were stained, destained,
dried, and autoradiographed at -70°C against X-Omat XAR5 films.
Proliferation Assays.
￿
PBMC, E` cells, or monocyte-depleted T cells (2 x 105 cells) in 200
j1 of complete medium were incubated in triplicate in flat-bottomed 96-well plates at 37°C
for 3 d in a 5% C02 atmosphere. During the last 9 h, cells were pulsed with 0 .4 ACi of
['H]thymidine (sp act 75 Ci/mmol; Amersham Corp., Arlington Heights, IL), and incor-
porated radioactivity was determined as described (17).
For some experiments, PHA-P (Difco Laboratories, Inc., Detroit, MI) was used for T cell
activation.
Immunofluorescence Studies.
￿
Cells were stained with mAb at 4°C for 30 min. After extensive
washing, the cells were further incubated with FITC-conjugated goat anti-mouse F(ab')2 at
4°C for 30 min. For the study on IL-2-R. expression, biotinylated AT-1 was used as the first
ligand, and FITC-conjugated avidin was used as the second ligand. After three washings,
the cells were analyzed with a CytofluorografIts cell sorter (Ortho Diagnostic Systems, Inc.,
Westwood, MA). Linear integrated fluorescence of the gated population was measured and
104 cells were analyzed. As negative controls, the cells were stained with nonbiotinylated AT-1
and FITC-avidin.
IL-2 Activity Assay.
￿
4 x 10' murine IL-2-dependent HT-2 cells in 100 J,1 of complete
medium, containing 2.5 x 10-5 M 2-ME were incubated with 100 ul of culture superna-
tants of serial twofold dilutions, in triplicate, at 37°C for 24 h. Then, 0.4 ttCi of [3H]thymi-
dine was added, and the incubation was continued for another 4 h. The incorporated radioac-
tivity was assayed as described above. rIL-2 (Biogen, Geneva, Switzerland) was used as a
standard, and IL-2 activity in culture supernatants was expressed in U/ml.
Northern Blot Hybridization.
￿
Methods for Northern blot analyses and sources ofprobes were
described previously (18).
Cytoplasmic Free Calcium Measurements.
￿
Cytoplasmic free [Ca2+]; was measured by a
modification of the method of Rabinovitch et al. (19), as described previously (8). Briefly,
cells were loaded with the acetoxymethyl esterof indo-1 (10 pM) (MolecularProbes, Eugene,
OR). Indo-l-loaded cells were analyzed by flow cytometry on a CytofluorografIts cell sorter.
UV excitation was from an argon ion laser (Coherent Inc., Palo Alto, CA) using 40 mW
at 351-364 nm. Blue (450-490 nm; Omega Optical, Inc., Brattleboro, VT) and violet (405
nm; Omega Optical, Inc.) band pass filters were used to collect into-1 fluorescence emission
after separation using a 430-nm dicroic mirror (Omega Optical, Inc.). Alterations in [Ca2. ];
were measured by analyzing the shift in the indo-1 ratio of violet to blue fluorescence over
a 15-min time period. UV excitation ofindo-1 in the absence of calcium results in the emis-
sion of light in the blue region. The binding of calcium to indo-1 shifts the UV excitation
emission of light from the blue region to the violet region. An increase in the indo-1 ratio
is a measurement of the increase in [Ca2. ];. At the beginning of each experiment, the violet
and blue photomultiplier tubes were adjusted to yield a basal ratio of 1.
Results
Identification ofmAb G38 andmAb Leu-23 as anti-EA 1 Antibody.
￿
BALB/c mice were
immunized with affinity-purified EA 1 molecules and hybridomas were generated
as described in Materials and Methods. Antibodies were rescreened for their reac-
tivity with PMA-activatedJurkat cells and by their ability to augment PMA-induced680
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T cell proliferation . One hybridoma, termed G38, was found to fulfill both selection
criteria . Hybridoma G38 was cloned twice on soft agar and mAb G38 was found
to be an IgG2b molecule.
The antigen reactive with mAb G38 was determined by immunoprecipitation from
a detergent lysate of 125I-labeled PMA-activated T cells and SDS-PAGE . As shown
in Fig . 1, the complex precipitated by mAb G38 was similar to that precipitated
by mAb P8, the original anti-EA 1 mAb reported previously (8) . Under reducing
conditions, both precipitated two bands of 28 and 32 kD (Fig . 1 A, lanes 2 and 3) .
Under nonreducing conditions, the EA 1 complex was resolved into 56- and 60-kD
bands with some trailing of the latter band (Fig. 1 A, lanes 5 and 6) . To further
prove that mAb G38 is reactive with EA 1, preclearing experiments were carried
out . As shown in Fig. 1, lanes 8 and 9, preclearing a 1251-labeled lysate with mAb
P8 completely removed the molecules reactive with mAb P8, as well as those precipi-
tated by mAb G38 . Similar results were obtained when mAb G38 was used as the
FIGURE 1 .
￿
mAb G38 and mAb Leu-23 immunoprecipitated EA 1 from PMA-activated T cells.
Peripheral blood T cells (5 x 106 cells/ml) incubated with 10 ng/ml ofPMA for 18 h were la-
beled with 1251 by lactoperoxidase . The lysate was precleared with Sepharose-4B beads conjugated
with goat anti-mouse Ig antibodies . Immunoprecipitation was carried out in these precleared
samples . Samples were analysed by SDS-PAGE under reducing (R) and nonreducing (NR) con-
ditions . (A) Sequential immunoprecipitation withmAb P8 andmAb G38. The precleared samples
were immunoprecipitated with pooled control mAbs (SSI and NS8 .1) (lanes 1, 4, 7, and 10),
mAb P8 (lanes 2, 5, 8, and 11), and mAb G38 (lanes 3, 6, 9, and 12) . (B) Sequential immunopre-
cipitation with mAb P8 and mAb Leu-23 . The precleared samples were immunoprecipitated
with pooled control mAbs (SS1 and HDP-1) (lanes 1, 4, and 7), mAb P8 (lanes 2, 5, and 8),
and mAb Leu-23 (lanes 3, 6, and 9) .NAKAMURA ET AL.
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preclearing Ab (Fig. 1, lanes 11 and 12). It is ofnote that the radioactivity ofmAb
G38 immunoprecipitates was higher than that ofmAb P8 immunoprecipitates. This
was observed in an additional experiment.
To determine whether mAb G38 was reactive with the same epitope as mAb P8,
biotinylated mAb P8was used with FITC-labeled avidin as the detecting agent. mAb
G38 did not block the staining ofmAb P8. By two-color immunofluorescence anal-
ysis, both mAbs stained the same population ofthymocytes and PMA-activated T
cells. These results indicate that mAb G38 recognizes a different epitope of EA 1.
Recently, Lanier et al. (10) and Chen et al. (20) reported the identification ofan
activation antigen, Leu-23, that is rapidly induced and phosphorylated after IL-2
stimulation ofNK cells. Since Leu-23 antigen has structural properties and a cel-
lulardistribution similarto EA 1, asequential immunoprecipitation experiment was
carried out todetermine whethermAbP8 andmAb Leu-23 were reactive with iden-
tical molecules. As shown in Fig. 1 B, both mAb P8 and mAb Leu-23 were reactive
with a similar molecular complex. Preclearing of 1251-labeled lysate of PMA-
activated T cells with mAb P8 completely removed molecules reactive with mAb
Leu-23 and vice versa (Fig. 1 B, lanes 6 and 8). These results indicate that mAb
Leu-23 also recognize EA 1. Again, it is of note that mAb Leu-23 appeared to be
a better precipitating antibody.
Augmentation ofPMA-inducedPBMC Proliferation by mAb G38.
￿
PBMC were stimu-
lated with 1 :100 diluted ascitic fluids or 1 :4 diluted culture supernatants ofhybrid-
omas G38 and P8 in the presence ofvarying doses of PMA. At all doses ofPMA,
both G38 ascitic fluid and supernatant augmented PMA-induced PBMC prolifera-
tion significantly with more than doubling the amounts of [3H]thymidine incorpo-
ration. A representative experiment is summarized in Table I. Two additional ex-
periments yielded similar results. In contrast, the effects of P8 ascitic fluid and
supernatant at the dilutions used were weak or not detectable.
EA 1 moleculesare also induced on cellsurface withPHA oranti-CD3 mAb stim-
ulation as described previously (7). We examined whether or not mAb G38 could
augment PBMC proliferation induced by suboptimal doses ofthese mitogens. In
these experiments, a trend ofaugmentation was detected. However, these effects were
only marginal at 20-30% augmentation (data not shown). In addition, augmenta-
tion was not detected in one additional experiment.
T Cell Proliferation Induced by Anti-EA 1 mAb in the Presence of PMA.
￿
PBMC, E+
cells with 1% contaminatingmonocytes, and T cells extensively depleted ofmono-
cytes were cultured with various doses of PMA and 1:100 diluted G38 ascites. As
shown inTable I, mAb G38 augmentedPMA-induced PBMC proliferation consider-
ably. In addition, it induced E+ cells and extensively purified Tcells to proliferate
in the presence ofPMA. The purified T cells were depleted ofmonocytes to <0.1%
by nylon wool column, plastic adherence, and carbonyl iron treatment. This T cell
population was nonresponsiveto PHA. These results indicate that the effect ofmAb
G38 is monocyte independent in this system.
To demonstrate that T cell proliferation induced by mAb G38 in the presence
ofPMA wasdose dependent, purifiedmAbwas used. As shown in TableII, purified
mAb G38 induced T cell proliferation in the presence ofPMA at a wide range of
mAb concentrations(0.5-100 ttg/ml) in adose-dependent manner. This is more ap-
parent when 3 ng/ml of PMA was used. In this experiment, purified mAb Leu-23682
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TABLE I
Effects of Anti-EA 1 mAb G38 on PMA-induced PBMC
and T Cell Proliferation
mAb G38 augmented PMA-induced PBMC and T cell proliferation. T cell
proliferation induced by PMA and mAb G38 was monocyte-independent.
PBMC, E' cells (1 % contaminating monocytes), monocyte-free T cells (2 x
105) were stimulated with mAb G38 in the presence of 10 ftg/ml of PHA or
various concentrations of PMA. [3H]Thymidine incorporation was measured
in triplicate after 3 d. SD of each value were within 15 % .
* G38 ascites were used at final dilution of 1 :100.
wasincluded and found to be very potent in this assay. mAb P8 was much less effec-
tive as a mitogen. Significantproliferationwas seen only at doses of50 and 100wg/ml.
Theseresultswere in agreement withthose inTable I. P8 ascites contained 2 mg/ml,
and at 1:100 dilution, mAb P8 was at 20 Fig/ml, a dose expected tobe slightly mito-
genic in the presence of PMA.
IL-2-R Expression and IL-2 Production.
￿
T cell activation with anti-EA 1 mAb G38
inthe presence ofPMA was associatedwith a marked increase in IL-2-R expression
as detectable by our mAb AT-1 (Fig. 2). Because the cells were cultured in the pres-
ence ofmouse mAb, biotinylated AT-1 was used with FITC-avidin. With medium
or mAb G38 alone, 6-8% of the T cells weakly expressed IL-2-R at all time points
studied (data not shown). Although PMA did not induce a high level ofprolifera-
tion, a significant number of T cells (34%) were positive for IL-2-R by 72 h. In
the presence ofmAb G38 andPMA, 80% ofTcells were positive by 24 h, and 900 /0
became strongly positive by 72 h. For comparison, IL-2-R expression induced by
PMA and anti-CD3 mAb T3-II was included in Fig. 2.
IL-2 production by T cells stimulated with mAb G38 in the presence of PMA
wasdetected 24h afterthe initiation ofcultures(Table III). Significant proliferation
ofHT-2 cellswas detected even whenthe supernatants were dilutedto 1 :32, although
the IL-2 activity was less than that in supernatants from cultures with mAb T3-II
Cell population Stimulating agents
[3H]Thymidine incorporation in
the presence of:
Medium mAb G38*
PBMC Medium 1,085 2,397
PHA 72,651 80,969
PMA (10 ng/ml) 11,001 76,311
PMA (3 ng/ml) 9,129 10,422
PMA (1 ng/ml) 3,280 5,684
E' Cells Medium 356 398
PHA 52,354 56,723
PMA (10 ng/ml) 4,342 63,413
PMA (3 rig/ml) 2,949 77,837
PMA (1 ng/ml) 2,004 50,803
Monocyte-free Medium 130 363
T cells PHA 1,367 1,161
PMA (10 ng/ml) 2,608 50,883
PMA (3 ng/ml) 2,351 65,463
PMA (1 ng/ml) 1,182 9,359NAKAMURA ET AL .
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TABLE II
T Cell Proliferation Induced by Purled Anti-EA 1 mAbs
in the Presence ofPMA Was Dose Dependent
T cells (E* cells) (2 x 10 5 ) were stimulated with various concentrations of
purified mAbs in the presence ofPMA . [ 3H]Thymidine incorporation was mea-
sured in triplicate after 3 d . SD of each value were within 15 % .
and PMA. The supernatant of T cells with PMA showed marginal level of IL-2
activities .
Expression ofIL-2and IL-2-R mRNA in T Cells Stimulatedwith mAbG38andPMA .
￿
The
observation thatT cell activation with mAb G38andPMA was associated with an
increase in IL-2-R expression and IL-2 secretion was substantiated at the mRNA
level . T cells were stimulated with mAb G38and PMA for 24 h and the induction
of IL-2 and IL-2-R mRNA synthesis was examined by Northern blot analysis . As
shown in Fig . 3, very little IL-2 mRNA accumulation was seen whenPMA wasused
alone . Although the accumulation ofIL-2-RmRNA wasbarely observed as presented
FIGURE 2 .
￿
Time course ofexpression ofIL-2-R
on T cells stimulated with anti-EA 1 mAb in the
presence of PMA. T cells (E+ cells) were cul-
tured with medium, PMA (10 ng/ml) alone,PMA
and mAb G38 (1 :100 diluted ascites), or PMA
and mAb T3-II (1 hg/ml) . IL-2-R` cells were
determined by biotinylated AT-1 and FITC-avidin
at the indicated times, as described in Materials
and Methods . Linear integrated fluorescence of
the gated population was measured in these ex-
periments .
Antibodies
[3H]Thymidine
0
incorporation at
concentration (ng/ml) of:
3
PMA
10
Ag/ml cpm
Medium 274 10,983 18,162
T3-11 10 1,027 80,780 81,767
G38 100 364 51,842 56,728
50 364 46,105 48,966
10 491 36,531 43,259
5 404 31,080 45,299
1 299 16,130 24,876
Lcu-23 10 228 76,404 74,698
1 435 45,164 52,435
P8 100 253 39,348 37,197
50 472 27,193 33,959
10 230 15,527 24,500
5 547 15,941 20,765
1 597 14,029 15,362
0 .5 372 11,718 17,352684
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TABLE III
IL-2 Production by T Cells Stimulated with Anti-EA 1 mAb
in the presence of PMA
T cells (E` cells) (10 6 cells/ml) were cultured in the presence of stimulator(s) .
10 ng/ml ofPMA and 1 jig/ml of T3-II were used . G38 ascites were used at
a final dilution of 1 :100 . After 24 h, supernatants were harvested and their abili-
ty to stimulate [3H]thymidine incorporation into murine IL-2-dependent HT-2
cells was determined . SD of each value were within 15% .
in Fig. 3, lane 4, the induction ofIL-2-R mRNA byPMA alonewas apparent where
autoradiography was carried out for a longer period of time . In contrast, mAb G38
and PMA in combination induced IL-2 mRNA synthesis to a readily detectable
level (Fig . 3, lane 5) . In addition, mAbG38increased PMA-induced IL-2-R mRNA
accumulation by ti 10-fold . ThesemRNA levels were comparable with those induced
by anti-CD3 mAb andPMA (Fig . 3, lane 2) . Although not shown, mAb G38 alone
did not induce any detectable IL-2 or IL-2-R mRNA synthesis .
Induction of[Ca21], Increase by mAb G38 after Crosslinking by Anti-mouse Ig Antibodies.
Changes in [Ca2+ ]i are shown to be an early event ofT cell activation . To determine
if mAb G38 could induce an increase in [Ca" ]i, monocyte-depleted T cells were
activatedwith 10 ng/ml ofPMAfor 18 h to induceEA 1 on cell surface before loading
with indo-1 . As a positive control, anti-CD3 mAb 235 (IgM) which is very potent
FIGURE 3 . Expression of IL-2 and IL-2-R
mRNA in T cells stimulated with anti-EA 1 mAb
in the presence ofPMA . T cells (E' cells) were
cultured with medium (lane 1), PMA (10 ng/ml)
and mAb T3-II (1 ug/ml) (lane 2), PHA (10
Wg/ml) (lane 3), PMA alone (lane 4), or PMA
andmAb G38 (1 :100 diluted ascites) (lane 5) for
24 h . RNA was extracted from samples of 5 x
10 1 lymphocytes. Northern blot hybridization to
IL-2, IL-2-R, and0 actin probes were performed
as described in Materials and Methods .
[ 3H]Thymidine incorporation
Culture at final dilutions of : IL-2
conditions 1 :2 1 :8 1 :32 1 :128 activity
U/ml
Medium 117 204 162 174 <0 .5
TPA 2,701 656 358 261 <0 .5
TPA + G38 43,061 19,954 4,903 751 7 .2
TPA + T3-11 47,389 56,995 38,368 10,592 71 .03.0 }
2.0 .
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FIGURE 4.
￿
Increasesin cytoplasmic-free
calcium levels inducedby anti-EA 1mAbs
in thepresence ofsecond antibodies. Mono-
cyte-depleted T cells (106 cells/ml) were
incubatedwith 10 ng/mlof PMAfor 18 h
before Indo-1 loading. Increases in [Ca2*Ji
were measured as describedin Materials
and Methods. An increase in the Indo-1
ratio reflects an increase in [Ca2+ li. 1,
mAb235(antiT3,IgM) (1 Ftg/ml); 2, mAb
G38 (10 Ag/ml) and goat anti-mouse Ig
antibodies (40lAg/ml); 3, mAb P8 (108g/
ml) and goat anti-mouse Ig antibodies; 4,
mAb G38 alone, mAb P8 alone, or goat
anti-mouse Ig antibodies alone. Signifi
t2
￿
is
￿
cant differences betweenmAbG38 alone,
mAb P8 alone, and goat anti-mouse Ig
antibodies alonewere notdetectable. For
simplicity, mAb G38 alonewas shown in
this figure.
in the induction ofa rise in [Ca2+]i, as described previously (8), was used. As shown
in Fig. 4, mAb 235 at 1 hg/ml induced a marked rise in [Ca2+]i, although TCR/
CD3 complexes were downregulated with PMA (Fig. 4, curve 1). In contrast, both
mAb G38 and mAb P8 by themselves did not induce a detectable change in [Ca2+]i.
However, the addition of goat anti-mouse Ig antibodies as the second antibodies
induced a significant rise in [Ca2+]i by mAb G38 (Fig. 4, curve 2). Although the
increase in [Ca2+ ]i was much smaller, mAb P8 at 10 kg/ml after crosslinking was
alsoeffectiveinthis assay (Fig. 4, curve3). Both anti-EA I mAbs and goatanti-mouse
Ig antibodies had no effect on [Ca2+ ], when monocyte-depleted T cells were used
without PMA activation.
Discussion
EA 1, an early activation antigen, was originally identified by our mAb P8 (7).
The antigen is a complex ofphosphorylated disulfide-linked dimers with a core poly-
peptide of24 kD that is differentially glycosylated to generate 28- and 32-kD glyco-
proteins (8). The inductive signal requirement for EA 1 expression appears to be
the activation of protein kinase C, although its maximal expression required the
participation ofCa2+-mediated pathways as well. The induction ofEA 1 is detect-
able within 30 min after the addition of PMA. It is the earliest T cell activation
antigen induced by PMA and other polyclonal mitogens, the expression of which
requires de novo RNA and protein synthesis. Recently, the expression ofEA 1 has
been documented by fetal thymocytes as early as 8-9 wk afterinception before thymic
cortico-medullary organization occurs (Jung, L. K. L., B. F. Haynes, S. Pahwa, and
S. M. Fu, manuscript submitted forpublication) . Its expression follows shortly after
the expression ofCD7 andCD2. Aftercortico-medullary organization, the majority
ofthe medullary thymocytes express EA 1. These findings indicate that EA 1 may
play an important role in T cell ontogeny and T cell activation.
In the present study, mAb G38, a new anti-EA 1 mAb, was shown to augment
PMA-induced PBMC proliferation. With T cell preparations extensively depleted686
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ofmonocytes, mAb G38 was capable to induce T cell proliferation in collaboration
with PMA in a dose-dependent manner. In certain experiments, the magnitude of
T cell proliferation induced by mAb G38 and PMA was comparable with that in-
ducedby anti-CD3 mAb andPMA. Antibodies specificforhormone orgrowth factor
receptors have been shown to mimic the functional effects of their ligands (21-24).
Thus, the collaborationbetween anti-EA 1 mAb andPMA toinduce Tcell prolifer-
ation provides direct evidence that EA 1 has a functional role in T cell activation.
However, the identification ofthe physiological ligand for EA 1, whichmaybeeither
a growth factor or a surface molecule involved in cell-cell interaction, remains to
be accomplished.
T cell proliferation induced by anti-EA 1 mAb andPMA was shown to be accom-
panied by IL-2-R expression and IL-2 secretion. This was demonstrated at both
protein and mRNA levels. mAb G38 potentiated the expression ofIL-2-R induced
byPMA and collaborated with PMA to induce IL-2 synthesis and secretion. These
findingstogetherwiththeobservation thattheactivation ofproteinkinase C issufficient
for EA 1 expression indicate that EA 1 may participate in T cell proliferation in
an autocrine system after the initial activation events.
The transduction signals delivered by anti-EA 1 mAbs to PMA-activated T cells
were investigated. Although anti-EA 1 mAbs did notinduce anappreciable increase
in [Ca2 +]i by themselves, the addition ofsecond goat anti-mouse Ig antibodies in-
duced marked influx of Cat+. Recently, Ledbetter et al. (25) reported mAbs specific
for CD2, CD4, CD5, CD6, CD7, CD8, and CD28 cause an increase in [Ca2+];
afterthese antigens are crosslinked on the cell surface. In their system, the increase
in [Ca2+ ]i after crosslinking of CD2 and CD28 appears to be associated with ex-
pression ofIL-2-R. mAbs to these two antigens are capable ofinducing T cells to
proliferate in thepresence ofPMA. Theexact signal transduction mechanisms used
by CD2 and CD28 have not been clearly defined. While CD2 pathway is linked to
the TCR/CD3 pathway, CD28 pathway is independent of the TCR/CD3 pathway.
Whetherthe EA 1 pathwayutilized a similarmechanism asthe CD28 pathwaydeserves
further exploration. In view ofthe recent observation that theCD28 pathwayis rela-
tively insensitive to cyclosporin A (26), it would be of interest to determine if the
EA 1 pathway is also resistant to this immunosuppressive agent.
The new anti-EA 1 mAb G38 was shown to react with an epitope different from
that with the initial anti-EA mAb P8. mAb G38 appears to have a higher binding
affinity. In adose-response experiment, it was demonstrated that a several-foldhigher
concentrationofmAb P8 was required toinduce detectable Tcell proliferation. This
indicates that the reactive epitopes, as well as binding affinity ofthe mAbs, are im-
portant in determining their mitogenic potential. In addition, the finding offers an
explanation for our initial unsuccessful attempt to demonstrate mitogenic effects
of mAb P8.
There are two mAbs in the literature that are very similar to our anti-EA 1 anti-
bodies. One ofthem is mAb Leu-23 (12). Leu-23 is rapidly induced on lymphocytes
by mitogen. The kinetics ofits expression is similar to EA 1. Leu-23 is alsoinduced
after IL-2 stimulation of NK cells. Appearance of Leu-23 on NK cells closely par-
allel IL-2-induced cytotoxicity. Ourdata showed that theantigen reactive withmAb
Leu-23 was identical with EA-1. Inaddition, mAbLeu-23 was alsoshownto be mito-
genic for T cells in collaboration with PMA. Thus, the demonstration of EA 1 onNAKAMURA ET AL.
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NK cells shows a broader cellular distribution. It adds support to the hypothesis
that EA 1 may have an important role in the general process involved with cellular
activation.
Cosulich et al. (27) also reported an early activation antigen identified by mAb
MLR 3 that is structurally similar to EA 1. It is of interest that mAb MLR3 inhibits
IL-1-dependent T cell or thymocyte proliferation. Although mAb P8 does not have
inhibitory effects on similar systems (unpublished data), effects of mAb G38 have
not been examined. Furthermore, Delia et al. (28) reported that mAb MLR3 alters
the thymidine uptake ofmitogen-treated lymphocytes; augmentation is detected when
cells are stimulatedwith PMA and ionomycin, and reduction is detected when stimu-
lated with PHA, respectively. Moreover, they are observable only when the cells are
depleted of monocytes. Unlike EA 1 and Leu-23, MLR3 is not expressed on un-
stimulated thymocytes (27), but is induced on activated fetal thymocytes (28). MLR3
is modulated on Jurkat cells cultured with IL-2, but EA 1 is not (unpublished data).
These differences suggest MLR3 is a distinct molecule. However, it is possible that
these mAbs recognize different epitopes on the same molecule. A direct comparison
is needed to resolve these differences in functional assay.
Summary
A new mAb G38 was generated against purified EA 1, an early activation antigen.
In immunoprecipitation, it was reactive with the same complex precipitated by the
initial anti-EA 1 mAb P8. mAb G38 augemented PMA-induced proliferation of
PBMC. It was shown to be mitogenic for purified T cells in collaboration with PMA
in a dose-dependent manner. This effect was independent of monocytes and other
accessory cells. mAb G38 augmented PMA-induced IL-2-R expression. In conjunction
with PMA, it induced IL-2 synthesis and secretion. Its effects on IL-2-R and IL-2
expression were documented at both protein and mRNA levels. Both anti-EA 1 mAbs
did not induce Ca" influx by themselves in PMA-treated T cells. However, the ad-
dition of second anti-mouse Ig antibodies induced readily detectable increases in
[Ca2 +] ;. Ca" -mediated pathways may be utilized as the transduction signal mech-
anisms. mAb Leu-23 was shown to be reactive with EA 1. mAb Leu-23 was also
mitogenic for T cells in the presence of PMA. These findings provide evidence for
a functional role for EA 1 in T cell activation and proliferation.
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